fashion -WSS

fashion

author：hotspot 2025-09-28 21:04:49 - browse：8

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Researchers tackle phage therapy hurdles for wider adoption

hotspot

WSS

Inequities make cancer less preventable for women: report

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Flagship Pioneering startup Sonata Therapeutics lays off 21

Wikipedia

fashion

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Wildfire smoke exposes gaps in outdoor worker protections

Obamacare plans could cover weight loss drugs

BioMarin wins approval for gene therapy to treat hemophilia A

Abridge raises $150m as clinical notes automation market heats up

How one medical school became remarkably diverse

Address the ethical violations that led to 'Three Identical Strangers'

At least 13 dead in Texas as scorching temps continue

Did you have Obamacare on your GOP debate bingo card?

focus

Ionis has late

Flagship Pioneering startup Sonata Therapeutics lays off 21

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Researchers tackle phage therapy hurdles for wider adoption

Data show record exodus of life scientists from academia

Listen: Who gets the credit for GLP

hotspot

focus

leisure time

focus